MedTrace Logo

Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

NCT00449280 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2013-06-12

No results posted yet for this study

Summary

The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib.

This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

Sorafenib

400mg BID (200 mg twice daily)

DRUG

Rapamycin

30mg once weekly

DRUG

Rapamycin

3mg once daily

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Ezra Cohen, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449280 on ClinicalTrials.gov